Market Research > Industries > Healthcare

Market Research: International Rx-to-OTC Switch
Forecasts

International Rx-to-OTC Switch Forecasts

Published October 2005

View PDF brochure

The fifth report in Kline’s Rx-to-OTC-switch series provides forecasts of switch-candidate brands and 14 therapeutic classes in nine major markets in Europe, Asia-Pacific, and North America from 2004 to 2009. The study offers realistic, up-to-date forecasts based on comprehensive primary research with industry executives in each country examined. It also provides insights on reimbursement and payers’ perspectives on switches, including direct input from government health ministries, third-party payers, and managed care organizations. The study includes a thorough review of regulatory issues in each country examined and an in-depth analysis of the retail environment for Rx-to-OTC switches. (Y581)

Australia • Japan • New Zealand • France • Germany • Italy • United Kingdom • Canada • United States

	ORDER ONLINE

You may submit an online request to subscribe to sections of this report, using a simple three-step process. After submitting your online request, you will then be contacted by a member of our global sales team to confirm the final price, and complete the transaction. Upon acceptance of your order, we will deliver the files in pdf format via email.

STEP 1 of 3

– Select the sections in which you are interested by clicking on the appropriate boxes:

FULL REPORT [US$ 41 500 (forty one thousand five hundred US Dollars)]

INTRODUCTION [US$ 0]

ASIA-PACIFIC

AUSTRALIA [US$ 6 500]

OVERVIEW [US$ 3 000]

Table 3A-1 SELECTED CHARACTERISTICS OF AUSTRALIA
Table 3A-2 HISTORY OF RX-TO-OTC SWITCH MEDICINES IN AUSTRALIA
Table 3A-3 RX-TO-OTC SWITCH LIKELIHOOD OF PROFILED PRODUCTS IN AUSTRALIA
Table 3A-4 OTC MARKET BREAKDOWN IN AUSTRALIA BY THERAPEUTIC CLASS, 2003
Table 3A-5 TOP TEN OTC MARKETERS IN AUSTRALIA, 2003
Figure 3A-1 MARKET SHARE OF MAJOR OTC MARKETERS IN AUSTRALIA, 2003
Table 3A-6 LIST OF RECENT RX-TO-OTC SUBMISSIONS IN AUSTRALIA AND THEIR APPROVAL STATUS

ANALGESICS [US$ 1 200]

OVERVIEW [US$ 400]

Table 3A1 1 MANUFACTURERS’ SALES OF OTC ANALGESICS IN AUSTRALIA, 2003
Table 3A1 2 MANUFACTURERS’ SALES OF RX ARTHRITIS PAIN RELIEVERS IN AUSTRALIA, 2003
Table 3A1 3 MANUFACTURERS’ SALES OF RX ANTI-MIGRAINE MEDICATIONS IN AUSTRALIA, 2003
Figure 3A1 1 EXPIRATIONS OF AUSTRALIAN PATENTS FOR ANALGESICS
Table 3A1 4 PRICES PAID BY PBS IN AUSTRALIA FOR ANALGESICS Table
3A1-5 SWITCH LIKELIHOOD OF ANALGESICS IN AUSTRALIA

CELEBREX [US$ 400]

Table 3A1 6 MANUFACTURERS SALES OF CELEBREX IN AUSTRALIA, 2001 TO 2003
Table 3A1 7 PRICES PAID BY PBS IN AUSTRALIA FOR ANALGESICS E

IMIGRAN [US$ 400]

Table 3A1-8 MANUFACTURER’S SALES OF IMIGRAN IN AUSTRALIA, 2001 TO 2003
Table 3A1-9 PRICES PAID BY PBS IN AUSTRALIA FOR ANALGESICS

ANTIFUNGALS [US$ 1 200]

OVERVIEW [US$ 400]

Table 3A2-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION ANTIFUNGAL PRODUCTS IN AUSTRALIA, 2003
Table 3A2-2 MANUFACTURERS’ SALES OF PRESCRIPTION ANTIFUNGAL PRODUCTS IN AUSTRALIA, 2003
Table 3A2-3 PRICES PAID BY PBS IN AUSTRALIA FOR ANTIFUNGALS
Figure 3A2-1 EXPIRATIONS OF AUSTRALIAN PATENTS FOR ANTIFUNGALS
Table 3A2-4 SWITCH LIKELIHOOD OF ANTIFUNGALS IN AUSTRALIA

FUNGILIN [US$ 400]

Table 3A2-5 MANUFACTURER’S SALES OF FUNGILIN IN AUSTRALIA, 2001 TO 2003
Table 3A2-6 PRICES PAID BY PBS IN AUSTRALIA FOR ANTIFUNGALS

SPORANOX [US$ 400]

Table 3A2-7 MANUFACTURER’S SALES OF SPORANOX IN AUSTRALIA, 2001 TO 2003
Table 3A2-8 PRICES PAID BY PBS IN AUSTRALIA FOR ANTIFUNGALS

CHOLESTEROL REDUCERS [US$ 1 600]

OVERVIEW [US$ 400]

Table 3A3 1 MANUFACTURERS’ SALES OF Rx CHOLESTEROL REDUCERS IN AUSTRALIA, 2003
Figure 3A3 1 EXPIRATIONS OF AUSTRALIAN PATENTS FOR CHOLESTEROL REDUCERS
Table 3A3 2 PRICES PAID BY PBS IN AUSTRALIA FOR CHOLESTEROL-LOWERING MEDICATIONS
Table 3A3-3 SWITCH LIKELIHOOD OF CHOLESTEROL REDUCERS IN AUSTRALIA

LIPITOR [US$ 400]

Table 3A3 4 MANUFACTURER’S SALES OF LIPITOR IN AUSTRALIA, 2001 TO 2003
Table 3A3 5 PRICES PAID BY PBS IN AUSTRALIA FOR PRESCRIPTION CHOLESTEROL REDUCERS
Table 3A3 6 PRICES PAID BY PBS IN AUSTRALIA FOR PRESCRIPTION LIPITOR

PRAVACHOL [US$ 400]

Table 3A3 7 MANUFACTURER’S SALES OF PRAVACHOL IN AUSTRALIA, 2001 TO 2003
Table 3A3 8 PRICES PAID BY PBS IN AUSTRALIA FOR PRESCRIPTION CHOLESTEROL REDUCERS
Table 3A3 9 PRICES PAID BY PBS IN AUSTRALIA FOR PRESCRIPTION PRAVACHOL

ZOCOR [US$ 400]

Table 3A3 10 MANUFACTURER’S SALES OF ZOCOR IN AUSTRALIA, 2001 TO 2003
Table 3A3 11 PRICES PAID BY PBS IN AUSTRIALIA FOR PRESCRIPTION CHOLESTEROL REDUCERS
Table 3A3 12 PRICES PAID BY PBS IN AUSTRIALIA FOR PRESCRIPTION ZOCOR

DIGESTIVES/PROTON PUMP INHIBITORS [US$ 1 600]

OVERVIEW [US$ 400]

Table 3A4 1 MANUFACTURERS’ SALES OF OTC DIGESTIVES IN AUSTRALIA, 2003
Table 3A4 2 MANUFACTURERS’ SALES OF PPIs IN AUSTRALIA, 2003 Figure
3A4 1 EXPIRATIONS OF AUSTRALIAN PATENTS FOR DIGESTIVES/PPIs Table
3A4 3 PRICES PAID BY PBS IN AUSTRALIA FOR DIGESTIVES/PPIs
Table 3A4-4 SWITCH LIKELIHOOD OF DIGESTIVES IN AUSTRALIA

LOSEC [US$ 400]

Table 3A4-5 MANUFACTURER’S SALES OF LOSEC IN AUSTRALIA, 2001 TO 2003
Table 3A4-6 PRICES PAID BY PBS IN AUSTRALIA FOR DIGESTIVES/PPIs
Table 3A4-7 PRICES PAID BY PBS IN AUSTRALIA FOR LOSEC

SOMAC [US$ 400]

Table 3A4 8 MANUFACTURER’S SALES OF SOMAC IN AUSTRALIA, 2001 TO 2003
Table 3A4 9 PRICES PAID BY PBS IN AUSTRALIA FOR DIGESTIVES/PPIs

ZOTON [US$ 400]

Table 3A4 11 MANUFACTURER’S SALES OF ZOTON IN AUSTRALIA, 2001 TO 2003
Table 3A4 12 PRICES PAID BY PBS IN AUSTRALIA FOR DIGESTIVES/PPIs Table
3A4 13 PRICES PAID BY PBS IN AUSTRALIA FOR ZOTON

INFLUENZA MEDICATIONS [US$ 1 200]

OVERVIEW [US$ 400]

Table 3A5 1 MANUFACTURERS’ SALES OF PRESCRIPTION ANTIVIRALS IN AUSTRALIA, 2003
Figure 3A5 1 EXPIRATIONS OF AUSTRALIAN PATENTS FOR INFLUENZA MEDICATIONS
Table 3A5 2 PRICES PAID BY THE CONSUMER IN AUSTRALIA FOR INFLUENZA MEDICATIONS
Table 3A5-3 SWITCH LIKELIHOOD OF INFLUENZA MEDICATIONS IN AUSTRALIA

RELENZA [US$ 400]

Table 3A5 4 MANUFACTURERS’ SALES OF RELENZA IN AUSTRALIA, 2001 TO 2003
Table 3A5 5 PRICES PAID BY THE CONSUMER IN AUSTRALIA FOR INFLUENZA MEDICATIONS

TAMIFLU [US$ 400]

Table 3A5 6 MANUFACTURERS’ SALES OF TAMIFLU IN AUSTRALIA, 2001 TO 2003
Table 3A5 7 PRICES PAID BY THE CONSUMER IN AUSTRALIA FOR INFLUENZA MEDICATIONS

JAPAN [US$ 6 500]

OVERVIEW [US$ 4 000]

Table 3B-1 SELECTED CHARACTERISTICS OF JAPAN
Table 3B-2 MANUFACTURERS’ SALES OF PRESCRIPTION AND OVER-THE-COUNTER DRUGS IN JAPAN BY THERAPEUTIC CLASS, 2003
Figure 3B-1 MARKET SHARES OF LEADING THERAPEUTIC CLASSES IN JAPAN, 2003
Table 3B-3 MANUFACTURERS’ SALES OF PHARMACEUTICAL DRUGS IN JAPAN BY SUPPLIER, 2003
Table 3B-4 MANUFACTURERS’ SALES OF RX-TO-OTC SWITCH DRUGS IN JAPAN BY THERAPEUTIC CLASS, 2003
Table 3B-5 MANUFACTURERS’ SALES OF PRESCRIPTION CARDIOVASCULAR DRUGS IN JAPAN, 2003
Table 3B-6 MANUFACTURERS’ SALES OF PRESCRIPTION CENTRAL NERVOUS SYSTEM DRUGS IN JAPAN, 2003
Table 3B-7 MANUFACTURERS’ SALES OF PRESCRIPTION DERMATOLOGIC PREPARATIONS IN JAPAN, 2003
Table 3B-8 MANUFACTURERS’ SALES OF PRESCRIPTION GASTRO-INTESTINAL PREPARATIONS IN JAPAN, 2003
Table 3B-9 MANUFACTURERS’ SALES OF PRESCRIPTION DIABETES MEDICATIONS IN JAPAN, 2003
Table 3B-10 MANUFACTURERS’ SALES OF PRESCRIPTION ALLERGY MEDICATIONS IN JAPAN, 2003
Table 3B-11 MANUFACTURERS’ SALES OF PRESCRIPTION BLOOD MEDICINES/ BLOOD PRODUCTS IN JAPAN, 2003
Table 3B-12 MANUFACTURERS’ SALES OF DRUG CLASSES THAT ARE SOLD EXCLUSIVELY AS PRESCRIPTION DRUGS IN JAPAN, 2003
Table 3B-13 MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS APPROVED FOR RX-TO-OTC SWITCH BY CATEGORY, 2003
Table 3B-14 MANUFACTURERS’ SALES OF PROFILED PRESCRIPTION DRUGS IN JAPAN, 2003
Figure 3B-2 ORGANIZATION OF JAPAN’S MINISTRY OF HEALTH, LABOUR AND WELFARE
Table 3B-15 SELECTED QUASI-DRUGS AND CORRESPONDING INDICATIONS IN JAPAN
Table 3B-16 SELECTED QUASI-DRUGS APPROVED BY MHLW IN JAPAN
Figure 3B-3 Rx-to-OTC SWITCH PROCESS IN JAPAN
Table 3B-17 MEMBERS OF MHLW’s COMMITTEE ON THE RATIONALIZATION OF APPROVAL AND EXAMINATION OF NONPRESCRIPTION DRUGS
Table 3B-18 LIST OF RECENT RX-TO-OTC SWITCHES IN JAPAN, 1983 TO 2003
Table 3B-19 RX-TO-OTC SWITCH LIKELIHOOD OF PROFILED PRODUCTS IN JAPAN

ALLERGY MEDICATIONS [US$ 1 600]

OVERVIEW [US$ 400]

Table 3B1-1 AVAILABLE PRESCRIPTION ALLERGY MEDICATIONS IN JAPAN, 2004
Table 3B1-2 AVAILABLE OTC ALLERGY MEDICATIONS IN JAPAN, 2004
Table 3B1-3 HISTORICAL MANUFACTURERS’ SALES OF PRESCRIPTION ALLERGY MEDICATIONS IN JAPAN, 2001 TO 2004
Table 3B1-4 MANUFACTURERS’ SALES OF PRESCRIPTION ALLERGY MEDICATIONS IN JAPAN, 2003
Figure 3B1-1 MARKET SHARES OF MAJOR PRESCRIPTION ALLERGY MEDICATIONS IN JAPAN, 2003
Table 3B1-5 HISTORICAL SALES OF OTC ALLERGY DRUGS IN JAPAN, 2001 TO 2004
Table 3B1-6 MANUFACTURERS’ SALES OF OTC ALLERGY MEDICATIONS IN JAPAN, 2003
Table 3B1-7 HISTORICAL RX-TO-OTC SWITCHES OF ALLERGY MEDICATIONS IN JAPAN, 1990 TO 2003
Figure 3B1-2 PATENT EXPIRATIONS FOR ALLERGY MEDICATIONS IN JAPAN
Table 3B1-8 PRICES PAID FOR PRESCRIPTION ALLERGY MEDICATIONS IN JAPAN
Table 3B1-9 SWITCH LIKELIHOOD OF ALLERGY MEDICATIONS IN JAPAN

CLARITIN [US$ 400]

Table 3B1-10 MANUFACTURERS’ SALES OF CLARITIN IN JAPAN, 2002 AND 2003
Table 3B1-11 PRICES PAID FOR PRESCRIPTION ALLERGY MEDICATIONS IN JAPAN

ONON [US$ 400]

Table 3B1-12 MANUFACTURERS’ SALES OF ONON IN JAPAN, 2001 TO 2003
Table 3B1-13 PRICES PAID FOR PRESCRIPTION ALLERGY MEDICATIONS IN JAPAN

ZYRTEC [US$ 400]

Table 3B1-15 PRICES PAID FOR PRESCRIPTION ALLERGY MEDICATIONS IN JAPAN

ANALGESICS [US$ 1 600]

OVERVIEW [US$ 400]

Table 3B2-1 SELECTED ANALGESICS MARKETED IN JAPAN BY SEGMENT
Table 3B2-2 HISTORICAL MANUFACTURERS’ SALES OF PRESCRIPTION ANALGESICS IN JAPAN, 2001 TO 2003
Figure 3B2-1 MARKET SHARES OF PRESCRIPTION ANALGESICS IN JAPAN, 2003
Table 3B2-4 MANUFACTURERS’ SALES OF OTC ANALGESICS IN JAPAN, 2003
Table 3B2-5 PREVIOUS RX-TO-OTC SWITCHES OF ANALGESICS IN JAPAN, 1985 TO 1998
Figure 3B2-2 EXPIRATIONS OF JAPANESE PATENTS FOR ANALGESICS
Table 3B2-6 PRICES PAID FOR PRESCRIPTION ANALGESICS IN JAPAN
Table 3B2-7 PRICES PAID FOR NONPRESCRIPTION ANALGESICS IN JAPAN
Table 3B2-8 SWITCH LIKELIHOOD OF ANALGESICS IN JAPAN

LOXONIN [US$ 400]

Table 3B2-9 MANUFACTURERS’ SALES OF LOXONIN IN JAPAN, 2001 TO 2003
Table 3B2-10 PRICES PAID FOR PRESCRIPTION ANALGESICS IN JAPAN
Table 3B2-11 PRICES PAID FOR NONPRESCRIPTION ANALGESICS IN JAPAN

MOBIC [US$ 400]

Table 3B2-12 MANUFACTURERS’ SALES OF MOBIC IN JAPAN, 2001 TO 2003
Table 3B2-13 PRICES PAID FOR PRESCRIPTION ANALGESICS IN JAPAN
Table 3B2-14 PRICES PAID FOR NONPRESCRIPTION ANALGESICS IN JAPAN

VOLTAREN [US$ 400]

Table 3B2-15 MANUFACTURERS’ SALES OF VOLTAREN IN JAPAN, 2001 TO 2003
Table 3B2-16 PRICES PAID FOR PRESCRIPTION ANALGESICS IN JAPAN
Table 3B2-17 PRICES PAID FOR NONPRESCRIPTION ANALGESICS IN JAPAN

CARDIOVASCULAR DRUGS [US$ 1 600]

OVERVIEW [US$ 400]

Table 3B3-1 MANUFACTURERS’ SALES OF PRESCRIPTION CHOLESTEROL REDUCERS IN JAPAN, 2003
Figure 3B3-1 MARKET SHARES OF PRESCRIPTION CHOLESTEROL REDUCERS IN JAPAN, 2003
Table 3B3-2 HISTORICAL MANUFACTURERS’ SALES OF PRESCRIPTION AND OTC CHOLESTEROL REDUCERS IN JAPAN, 2001 TO 2003
Table 3B3-3 MANUFACTURERS’ SALES OF PRESCRIPTION ANTIHYPERTENSION DRUGS IN JAPAN, 2001 TO 2003
Table 3B3-4 MANUFACTURERS’ SALES OF PRESCRIPTION ANTIHYPERTENSION DRUGS IN JAPAN BY BRAND, 2003
Figure 3B3-2 MARKET SHARES OF PRESCRIPTION HYPERTENSION MEDICATIONS IN JAPAN BY SEGMENT, 2003
Table 3B3-5 RX-TO-OTC SWITCHES OF CHOLESTEROL REDUCERS IN JAPAN, 1983 TO 2004
Table 3B3-6 MANUFACTURERS’ SALES OF NONPRESCRIPTION CHOLESTEROL REDUCERS IN JAPAN, 2003
Table 3B3-7 PRICES PAID FOR PRESCRIPTION CHOLESTEROL REDUCERS DRUGS IN JAPAN
Table 3B3-8 SWITCH LIKELIHOOD OF CARDIOVASCULAR DRUGS IN JAPAN

BEZATOL [US$ 400]

Table 3B3-9 MANUFACTURERS’ SALES OF BEZATOL IN JAPAN, 2001 TO 2003
Table 3B3-10 PRICES PAID FOR PRESCRIPTION CHOLESTEROL REDUCERS IN JAPAN

EPADEL [US$ 400]

Table 3B3-11 MANUFACTURES’ SALES OF EPADEL IN JAPAN, 2001 TO 2003
Table 3B3-12 PRICES PAID FOR PRESCRIPTION CARDIOVASCULAR DRUGS IN JAPAN

MEVALOTIN [US$ 400]

Table 3B3-13 MANUFACTURERS’ SALES OF MEVALOTIN IN JAPAN, 2001 TO 2004
Table 3B3-14 PRICES PAID FOR PRESCRIPTION CHOLESTEROL REDUCERS IN JAPAN

COUGH/ASTHMA MEDICATIONS [US$ 1 200]

OVERVIEW [US$ 400]

Table 3B4-2 AVAILABLE PRESCRIPTION COUGH/ASTHMA MEDICATIONS IN JAPAN, 2004
Table 3B4-3 MANUFACTURERS’ SALES OF PRESCRIPTION COUGH/ASTHMA MEDICINES BY SEGMENT, 2003
Figure 3B4-1 MARKET SHARES OF PRESCRIPTION COUGH/ASTHMA MEDICATIONS IN JAPAN BY SEGMENT, 2003
Table 3B4-4 MANUFACTURERS’ SALES OF PRESCRIPTION COUGH AND ASTHMA MEDICATIONS IN JAPAN BY PRODUCT, 2003
Table 3B4-5 MANUFACTURERS’ SALES OF NONPRESCRIPTION COUGH AND ASTHMA DRUGS IN JAPAN, 2003
Figure 3B4-2 EXPIRATIONS OF JAPANESE PATENTS FOR PRESCRIPTION COUGH/ASTHMA MEDICATIONS
Table 3B4-6 EXPIRATIONS OF JAPANESE PATENTS FOR OTC COUGH/ASTHMA DRUGS IN JAPAN
Table 3B4-7 HISTORICAL RX-TO-OTC SWITCHES OF COUGH/ASTHMA AND RELATED MEDICATIONS IN JAPAN, 1985 TO 2003
Table 3B4-8 PRICES PAID FOR PRESCRIPTION COUGH/ ASTHMA MEDICATIONS IN JAPAN
Table 3B4-9 PRICES PAID FOR OTC COUGH/ASTHMA MEDICATIONS IN JAPAN
Table 3B4-10 SWITCH LIKELIHOOD OF COUGH/ASTHMA MEDICATIONS IN JAPAN

MUCODYNE [US$ 400]

Table 3B4-11 MANUFACTURERS’ SALES OF MUCODYNE IN JAPAN, 2001 TO 2004
Table 3B4-12 PRICES PAID FOR PRESCRIPTION COUGH/ASTHMA MEDICATIONS IN JAPAN

MUCOSOLVAN [US$ 400]

Table 3B4-14 MANUFACTURERS’ SALES OF MUCOSOLVAN IN JAPAN, 2001 TO 2004
Table 3B4-15 PRICES PAID FOR PRESCRIPTION COUGH/ASTHMA MEDICATIONS IN JAPAN

ONON [US$ 400]

Table 3B4-17 MANUFACTURERS’ SALES OF ONON IN JAPAN, 2001 TO 2004
Table 3B4-18 PRICES PAID FOR PRESCRIPTION COUGH/ASTHMA MEDICATIONS IN JAPAN
Table 3B4-19 PRICES PAID FOR OTC COUGH/ASTHMA MEDICATIONS IN JAPAN

ERECTILE DYSFUNCTION MEDICATIONS [US$ 800]

OVERVIEW [US$ 400]

Figure 3B5-1 EXPIRATIONS OF JAPANESE PATENTS FOR ERECTILE DYSFUNCTION MEDICATIONS
Table 3B5-2 SWITCH LIKELIHOOD OF ERECTILE DYSFUNCTION DRUGS IN JAPAN

VIAGRA [US$ 400]

Table 3B5-3 MANUFACTURERS’ SALES OF VIAGRA IN JAPAN, 2001 TO 2004

ANTI-OBESITY DRUGS [US$ 800]

OVERVIEW [US$ 400]

Table 3B6-2 MANUFACTURERS’ SALES OF OTC ANTI-OBESITY DRUGS IN JAPAN, 2003
Table 3B6-4 SPECIFIED SUPPLEMENT FOODS AND HEALTH FOODS FOR TREATING OBESITY IN JAPAN

SANOREX [US$ 400]

Table 3B6-6 MANUFACTURERS’ SALES OF SANOREX IN JAPAN, 2001 TO 2004

NEW ZEALAND [US$ 6 500]

OVERVIEW [US$ 3 000]

Table 3C-1 SELECTED CHARACTERISTICS OF NEW ZEALAND
Table 3C-2 ESTIMATED DTC ADVERTISING EXPENDITURES FOR BOTH PRESCRIPTION AND OTC DRUGS IN NEW ZEALAND BY MEDIA CATEGORY, 2000
Table 3C-3 HISTORY OF SELECT RX-TO-OTC SWITCHES IN NEW ZEALAND
Table 3C-4 RX-TO-OTC SWITCH LIKELIHOOD OF PROFILED PRODUCTS IN NEW ZEALAND
Table 3C-6 OTC MARKET BREAKDOWN IN NEW ZEALAND BY THERAPEUTIC CLASS, 2003
Table 3C-7 SALES OF OTC MARKETERS IN NEW ZEALAND, 2003
Figure 3C-1 MARKET SHARE OF MAJOR OTC MARKETERS IN NEW ZEALAND, 2003
Table 3C-5 LIST OF RECENT RX-TO-OTC SUBMISSIONS IN NEW ZEALAND AND THEIR APPROVAL STATUS.

ANALGESICS [US$ 1 200]

OVERVIEW [US$ 400]

Table 3C1-1 MANUFACTURERS’ SALES OF OTC ANALGESICS IN NEW ZEALAND, 2003
Table 3C1-2 MANUFACTURERS’ SALES OF Rx ARTHRITIS PAIN RELIEVERS IN NEW ZEALAND, 2003
Table 3C1-3 MANUFACTURERS’ SALES OF Rx ANTIMIGRAINE MEDICATIONS IN NEW ZEALAND, 2003
Figure 3C1-1 EXPIRATIONS OF NEW ZEALAND PATENTS FOR ANALGESICS
Table 3C1-4 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR ANALGESICS
Table 3C1-5 SWITCH LIKELIHOOD OF ANALGESICS PRODUCTS IN NEW ZEALAND

CELEBREX [US$ 400]

Table 3C1-6 MANUFACTURER’S SALES OF CELEBREX IN NEW ZEALAND, 2001 TO 2003
Table 3C1-7 PFIZER’S SALES OF NONPRESCRIPTION DRUGS IN NEW ZEALAND, 2003

IMIGRAN [US$ 400]

Table 3C1-8 MANUFACTURER’S SALES OF IMIGRAN IN NEW ZEALAND, 2001 TO 2003
Table 3C1-9 GLAXOSMITHKLINE’S SALES OF NONPRESCRIPTION DRUGS, 2003
Table 3C1-10 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR ANALGESICS

CHOLESTEROL REDUCERS [US$ 1 200]

OVERVIEW [US$ 400]

Table 3C2-1 MANUFACTURERS’ SALES OF STATINS IN NEW ZEALAND, 2003
Figure 3C2-1 EXPIRATIONS OF NEW ZEALAND PATENTS FOR CHOLESTEROL REDUCERS
Table 3C2-2 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR CHOLESTEROL REDUCERS
Table 3C2-3 SWITCH LIKELIHOOD OF CHOLESTEROL REDUCER PRODUCTS IN NEW ZEALAND

LIPEX [US$ 400]

Table 3C2-4 MANUFACTURER’S SALES OF LIPEX IN NEW ZEALAND, 2002 AND 2003
Table 3C2-5 MANUFACTURER’S SALES OF ZOCOR IN NEW ZEALAND, 2001 AND 2002
Table 3C2-6 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR CHOLESTEROL REDUCERS
Table 3C2-7 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR LIPEX/ZOCOR

LIPITOR [US$ 400]

Table 3C2-8 MANUFACTURER’S SALES OF LIPITOR IN NEW ZEALAND, 2001 TO 2003
Table 3C2-9 SALES OF PFIZER’S NONPRESCRIPTION DRUGS, 2003
Table 3C2-10 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR CHOLESTEROL REDUCERS
Table 3C2-11 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR LIPITOR

DIGESTIVES/PROTON PUMP INHIBITORS [US$ 1 600]

OVERVIEW [US$ 400]

Table 3C3-1 MANUFACTURERS’ SALES OF OTC DIGESTIVES IN NEW ZEALAND, 2003
Table 3C3-2 MANUFACTURERS’ SALES OF PRESCRIPTION PPIs IN NEW ZEALAND, 2003
Table 3C3-3 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR DIGESTIVES/PPIs
Figure 3C3-1 EXPIRATIONS OF NEW ZEALAND PATENTS FOR DIGESTIVES/PPIs
Table 3C3-4 SWITCH LIKELIHOOD OF DIGESTIVE/PPI PRODUCTS IN NEW ZEALAND

LOSEC [US$ 400]

Table 3C3-5 MANUFACTURER’S SALES OF LOSEC IN NEW ZEALAND, 2001 TO 2003
Table 3C3-6 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR DIGESTIVES/PPIs

SOMAC [US$ 400]

Table 3C3-7 MANUFACTURER’S SALES OF SOMAC IN NEW ZEALAND, 2001 TO 2003
Table 3C3-8 PFIZER’S SALES OF NONPRESCRIPTION DRUGS, 2003
Table 3C3-9 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR DIGESTIVES/PPIs

ZOTON [US$ 400]

Table 3C3-10 MANUFACTURER’S SALES OF ZOTON IN NEW ZEALAND, 2001 TO 2003
Table 3C3-11 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR DIGESTIVES/PPIs

INFLUENZA MEDICATIONS [US$ 1 200]

OVERVIEW [US$ 400]

Table 3C4-1 MANUFACTURERS’ SALES OF OTC COLD AND FLU MEDICATIONS IN NEW ZEALAND, 2003
Table 3C4-2 MANUFACTURERS’ SALES OF PRESCRIPTION INFLUENZA MEDICATIONS IN NEW ZEALAND, 2003
Table 3C4-3 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR INFLUENZA MEDICATIONS
Figure 3C4-1 EXPIRATIONS OF NEW ZEALAND PATENTS FOR INFLUENZA MEDICATIONS
Table 3C4-4 SWITCH LIKELIHOOD OF INFLUENZA MEDICATIONS IN NEW ZEALAND

RELENZA [US$ 400]

Table 3C4-5 MANUFACTURER’S SALES OF RELENZA IN NEW ZEALAND, 2001 TO 2003
Table 3C4-6 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR INFLUENZA MEDICATIONS

TAMIFLU [US$ 400]

Table 3C4-7 MANUFACTURER’S SALES OF TAMIFLU IN NEW ZEALAND, 2001 TO 2003
Table 3C4-8 PRICES PAID BY PHARMAC IN NEW ZEALAND FOR INFLUENZA MEDICATIONS

ANTI-OBESITY DRUGS [US$ 800]

OVERVIEW [US$ 400]

Table 3C5-1 MANUFACTURERS’ SALES OF ANTI-OBESITY DRUGS IN NEW ZEALAND, 2003

XENICAL [US$ 400]

Table 3C5-2 MANUFACTURER’S SALES OF XENICAL IN NEW ZEALAND, 2001 TO 2003

ORAL CONTRACEPTIVES [US$ 600]

OVERVIEW [US$ 400]

Table 3C6-1 MANUFACTURERS’ SALES OF PRESCRIPTION HORMONAL CONTRACEPTIVES IN NEW ZEALAND, 2003

POSTINOR-2 [US$ 400]

Table 3C6-2 MANUFACTURER’S SALES OF POSTINOR-2 IN NEW ZEALAND, 2001 TO 2003
Table 3C6-3 MANUFACTURER’S SALES OF LEVONELLE IN NEW ZEALAND, 2001 TO 2003
Table 3C6-4 SCHERING’S SALES OF ORAL CONTRACEPTIVES IN NEW ZEALAND, 2003

EUROPE

Table 4-1 TOP PHARMACEUTICAL MARKETS IN THE EUROPEAN UNION, 2003
Figure 4-1 MARKET SHARES OF THE TOP PHARMACEUTICAL MARKETS IN THE EUROPEAN UNION, 2003
Table 4-2 PHARMACEUTICAL REVENUE OF LEADING COMPANIES IN THE EUROPEAN UNION, 2003
Figure 4-2 MARKET SHARES OF THE LEADING PHARMACEUTICAL COMPANIES IN THE EUROPEAN UNION, 2003
Figure 4-3 THE EUROPEAN UNION CENTRALIZED SYSTEM
Figure 4-4 THE EUROPEAN MUTUAL RECOGNITION SYSTEM

FRANCE [US$ 6 500]

OVERVIEW [US$ 4 000]

Table 4A-1 SELECTED CHARACTERISTICS OF FRANCE
Table 4A-4 MANUFACTURERS’ SALES GROWTH OF THE PHARMACEUTICAL MARKET IN FRANCE, 2000 TO 2003
Table 4A-5 MANUFACTURERS’ SALES OF PRESCRIPTION DRUGS IN FRANCE BY THERAPEUTIC CLASS, 2003
Figure 4A-1 MARKET SHARES OF LEADING THERAPEUTIC CLASSES IN FRANCE, 2003
Table 4A-6 MANUFACTURERS’ SALES OF TOP TEN RX PHARMACEUTICAL DRUGS IN FRANCE, 2003
Table 4A-9 RX-TO-OTC SWITCH LIKELIHOOD OF PROFILED PRODUCTS IN FRANCE

ANALGESICS AND ANTIRHEUMATICS [US$ 1 200]

Table 4A1-1 HISTORICAL SALES OF PRESCRIPTION ANALGESICS AND ANTIRHEUMATICS IN FRANCE, 2001 TO 2003
Table 4A1-2 MANUFACTURERS’ SALES OF OTC ANALGESICS AND ANTIRHEUMATICS IN FRANCE, 2000 TO 2003
Table 4A1-3 MANUFACTURERS’ SALES OF LEADING PRESCRIPTION ANALGESICS IN FRANCE, 2003
Figure 4A1-1 MARKET SHARES OF PRESCRIPTION ANALGESICS IN FRANCE, 2003
Table 4A1-4 SELECTED RX-TO-OTC SWITCHES OF ANALGESIC DRUGS IN FRANCE
Table 4A1-5 PRICES PAID BY THE GOVERNMENT FOR ANALGESICS IN FRANCE
Table 4A1-6 SWITCH LIKELIHOOD OF ANALGESICS AND ANTIRHEUMATICS IN FRANCE

OVERVIEW [US$ 400]

DOLOBIS [US$ 400]

Table 4A1-7 MANUFACTURERS’ SALES OF DOLOBIS IN FRANCE, 2001 TO 2003

VOLTAREN [US$ 400]

Table 4A1-9 MANUFACTURERS’ SALES OF VOLTAREN IN FRANCE, 2001 TO 2003
Table 4A1-10 PRICES PAID BY THE GOVERNMENT FOR ANALGESICS IN FRANCE

CHOLESTEROL REDUCERS [US$ 1 600]

OVERVIEW [US$ 400]

Table 4A2-1 HISTORICAL MANUFACTURERS’ SALES OF PRESCRIPTION CHOLESTEROL REDUCERS IN FRANCE, 2001 TO 2003
Table 4A2-2 MANUFACTURERS’ SALES OF PRESCRIPTION CHOLESTEROL REDUCERS IN FRANCE, 2003
Figure 4A2-1 MARKET SHARES OF PRESCRIPTION CHOLESTEROL REDUCERS IN FRANCE, 2003
Table 4A2-3 SWITCH LIKELIHOOD OF CHOLESTEROL REDUCERS IN FRANCE

ELISOR [US$ 400]

Table 4A2-4 MANUFACTURERS’ SALES OF ELISOR IN FRANCE, 2001 TO 2003
Table 4A2-5 PRICES PAID BY THE FRENCH GOVERNMENT FOR CHOLESTEROL REDUCERS

TAHOR [US$ 400]

Table 4A2-6 MANUFACTURER’S SALES OF TAHOR IN FRANCE, 2001 TO 2003
Table 4A2-7 PRICES PAID BY THE FRENCH GOVERNMENT FOR CHOLESTEROL REDUCERS

ZOCOR [US$ 400]

Table 4A2-8 MANUFACTURER’S SALES OF ZOCOR IN FRANCE, 2001 TO 2003
Table 4A2-9 PRICES PAID BY THE FRENCH GOVERNMENT FOR CHOLESTEROL REDUCERS

DIABETES MEDICATIONS [US$ 400]

Table 4A3-1 HISTORICAL SALES OF PRESCRIPTION DIABETES MEDICATIONS IN FRANCE, 2001 TO 2003
Table 4A3-2 MANUFACTURERS’ SALES OF LEADING DIABETES MEDICATIONS IN FRANCE, 2003
Figure 4A3-1 MARKET SHARES OF LEADING DIABETES MEDICATIONS IN FRANCE, 2003
Figure 4A3-2 EXPIRATIONS OF FRENCH PATENTS FOR DIABETES MEDICATIONS
Table 4A3-3 SWITCH LIKELIHOOD OF DIABETES MEDICATIONS IN FRANCE

DIGESTIVES/PROTON PUMP INHIBITORS [US$ 1 600]

OVERVIEW [US$ 400]

Table 4A4-1 HISTORICAL SALES OF PRESCRIPTION ANTI-ULCER DRUGS IN FRANCE,2001 TO 2003
Table 4A4-2 HISTORICAL SALES OF SELF-MEDICATION DIGESTIVES IN FRANCE, 2000 TO 2003
Figure 4A4-1 MARKET SHARES OF PRESCRIPTION PPIs IN FRANCE, 2003
Table 4A4-3 MANUFACTURERS’ SALES OF LEADING PRESCRIPTION PPIs IN FRANCE, 2003
Table 4A4-4 SELECTED RX-TO-OTC SWITCHES OF ANTI-ULCER DRUGS IN FRANCE
Figure 4A4-2 EXPIRATIONS OF FRENCH PATENTS FOR PPIs

LANZOR [US$ 400]

Table 4A4-6 MANUFACTURERS’ SALES OF LANZOR IN FRANCE, 2001 TO 2003
Table 4A4-7 PRICES PAID BY THE FRENCH GOVERNMENT FOR PPIs

MOPRAL [US$ 400]

Table 4A4-8 MANUFACTURERS’ SALES OF MOPRAL IN FRANCE, 2001 TO 2003
Table 4A4-9 PRICES PAID BY THE FRENCH GOVERNMENT FOR PPIs

OGAST [US$ 400]

Table 4A4-10 MANUFACTURERS’ SALES OF OGAST IN FRANCE, 2001 TO 2003
Table 4A4-11 PRICES PAID BY THE FRENCH GOVERNMENT FOR PPIs

HYPERTENTION MEDICATIONS [US$ 1 600]

OVERVIEW [US$ 400]

Table 4A5-1 HISTORICAL SALES OF PRESCRIPTION HYPERTENSION MEDICATIONS IN FRANCE, 2001 TO 2003
Table 4A5-2 MANUFACTURERS’ SALES OF PRESCRIPTION HYPERTENSION MEDICATIONS IN FRANCE, 2003
Figure 4A5-2 EXPIRATIONS OF FRENCH PATENTS FOR HYPERTENSION MEDICATIONS
Table 4A5-3 SWITCH LIKELIHOOD OF HYPERTENSION MEDICATIONS IN FRANCE

AMLOR [US$ 400]

Table 4A5-4 MANUFACTURERS’ SALES OF AMLOR IN FRANCE, 2001 TO 2003
Table 4A5-5 PRICES PAID BY THE FRENCH GOVERNMENT FOR HYPERTENSION MEDICATIONS

APROVEL [US$ 400]

Table 4A5-6 MANUFACTURERS’ SALES OF APROVEL IN FRANCE, 2001 TO 2003
Table 4A5-7 PRICES PAID BY THE FRENCH GOVERNMENT FOR HYPERTENSION MEDICATIONS

TRIATEC [US$ 400]

Table 4A5-8 MANUFACTURERS’ SALES OF TRIATEC IN FRANCE, 2001 TO 2003
Table 4A5-9 PRICES PAID BY THE FRENCH GOVERNMENT FOR HYPERTENSION MEDICATIONS

GERMANY [US$ 8 000]

OVERVIEW [US$ 3 000]

Table 4B-1 SELECTED CHARACTERISTICS OF GERMANY
Table 4B-2 MANUFACTURERS’ SALES OF PHARMACEUTICALS IN GERMANY, 2003
Table 4B-3 SALES OF PRESCRIPTION DRUGS IN GERMANY BY THERAPEUTIC CLASS, 2003
Figure 4B-1 PHARMACY SALES OF DRUGS IN GERMANY, 2003
Table 4B-4 TOP FIVE SELF-MEDICATION PRODUCT GROUPS IN GERMANY, 2001 TO 2003
Table 4B-5 RX-TO-OTC SWITCH CRITERIA IN GERMANY
Figure 4B-2 COMPONENTS OF RETAIL PHARMACY PRICES IN GERMANY
Table 4B-6 HISTORICAL RX-TO-OTC SWITCHES IN GERMANY
Table 4B-7 LIST OF RECENT RX-TO-OTC SWITCHES IN GERMANY
Table 4B-8 RX-TO-OTC SWITCH LIKELIHOOD OF PROFILED PRODUCTS IN GERMANY

ANALGESICS [US$ 400]

Table 4B1-1 HISTORICAL SALES OF PRESCRIPTION ANALGESICS IN GERMANY, 2001 TO 2003
Table 4B1-2 MANUFACTURERS’ SALES OF PRESCRIPTION ANALGESICS IN GERMANY, 2003
Table 4B1-3 SALES OF OTC ANALGESICS IN GERMANY BY SEGMENT, 2003
Table 4B1-4 MANUFACTURERS’ SALES OF KEY OTC ANALGESIC PRODUCTS IN GERMANY, 2003
Table 4B1-5 SWITCH LIKELIHOOD OF ANALGESICS IN GERMANY

ANTIFUNGALS [US$ 1 600]

OVERVIEW [US$ 400]

Table 4B2-1 HISTORICAL SALES OF PRESCRIPTION ANTIFUNGALS IN GERMANY, 2001 TO 2003
Table 4B2-2 SALES OF PRESCRIPTION ANTIFUNGALS IN GERMANY, 2003
Figure 4B2-1 EXPIRATIONS OF GERMAN PATENTS FOR ANTIFUNGALS
Table 4B2-3 PRICES PAID BY THE GOVERNMENT FOR ANTIFUNGALS IN GERMANY
Table 4B2-4 SWITCH LIKELIHOOD OF ANTIFUNGALS IN GERMANY

DIFLUCAN [US$ 400]

Table 4B2-5 MANUFACTURER’S SALES OF PRESCRIPTION DIFLUCAN IN GERMANY, 2001 TO 2003
Table 4B2-6 PRICES PAID BY THE GOVERNMENT FOR ANTIFUNGALS IN GERMANY

LAMISIL [US$ 400]

Table 4B2-7 MANUFACTURER’S PRESCRIPTION SALES OF LAMISIL IN GERMANY, 2001 TO 2003
Table 4B2-8 PRICES PAID BY THE GOVERNMENT FOR ANTIFUNGALS IN GERMANY

NIZORAL [US$ 400]

Table 4B2-9 MANUFACTURER’S SALES OF PRESCRIPTION NIZORAL IN GERMANY, 2001 TO 2003
Table 4B2-10 PRICES PAID BY THE GOVERNMENT FOR ANTIFUNGALS IN GERMANY

CHOLESTEROL REDUCERS [US$ 2 400]

OVERVIEW [US$ 400]

Table 4B3-1 HISTORICAL SALES OF PRESCRIPTION CHOLESTEROL REDUCERS IN GERMANY, 2001 TO 2003
Table 4B3-2 MANUFACTURERS’ SALES OF CHOLESTEROL REDUCERS IN GERMANY, 2003
Table 4B3-3 PRICES PAID BY THE GOVERNMENT FOR CHOLESTEROL REDUCERS IN GERMANY
Figure 4B3-1 EXPIRATIONS OF GERMAN PATENTS FOR CHOLESTEROL REDUCERS
Table 4B3-4 SWITCH LIKELIHOOD OF CHOLESTEROL REDUCERS IN GERMANY

CRESTOR [US$ 400]

Table 4B3-5 PRICES PAID BY THE GOVERNMENT FOR CHOLESTEROL REDUCERS IN GERMANY

LESCOL [US$ 400]

Table 4B3-6 MANUFACTURER’S SALES OF LESCOL IN GERMANY, 2001 TO 2003
Table 4B3-7 PRICES PAID BY THE GOVERNMENT FOR CHOLESTEROL REDUCERS IN GERMANY

PRAVASIN [US$ 400]

Table 4B3-8 MANUFACTURER’S SALES OF PRAVASIN IN GERMANY, 2001 TO 2003
Table 4B3-9 PRICES PAID BY THE GOVERNMENT FOR CHOLESTEROL REDUCERS IN GERMANY

SORTIS/LIPITOR [US$ 400]

Table 4B3-10 MANUFACTURER’S SALES OF SORTIS/LIPITOR IN GERMANY, 2001 TO 2003
Table 4B3-11 PRICES PAID BY THE GOVERNMENT FOR CHOLESTEROL REDUCERS IN GERMANY

ZOCOR [US$ 400]

Table 4B3-12 MANUFACTURER’S SALES OF ZOCOR IN GERMANY, 2001 TO 2003
Table 4B3-13 PRICES PAID BY THE GOVERNMENT FOR CHOLESTEROL REDUCERS IN GERMANY

DIABETES MEDICATIONS [US$ 400]

Table 4B4-1 RETAIL SALES OF SELECT BRANDED INSULIN IN GERMANY, 2003
Table 4B4-2 HISTORICAL SALES OF PRESCRIPTION ANTIDIABETES MEDICATIONS IN GERMANY, 2001 TO 2003
Table 4B4-3 SALES OF PRESCRIPTION ORAL ANTIDIABETES DRUGS IN GERMANY, 2003
Table 4B4-4 PRICES PAID BY THE GOVERNMENT FOR DIABETES MEDICATIONS IN GERMANY
Figure 4B4-1 EXPIRATIONS OF GERMAN PATENTS FOR DIABETES MEDICATIONS

DIGESTIVES/PROTON PUMP INHIBITORS[US$ 2 400]

Table 4B5-1 HISTORICAL SALES OF PRESCRIPTION DIGESTIVES/PPIs IN GERMANY, 2001 TO 2003
Table 4B5-2 SALES OF PRESCRIPTION PPIs IN GERMANY, 2003
Table 4B5-3 SALES OF THE LEADING OTC DIGESTIVES IN GERMANY, 2003
Table 4B5-4 PRICES PAID BY THE GOVERNMENT FOR DIGESTIVES/PPIs IN GERMANY
Figure 4B5-1 EXPIRATIONS OF GERMAN PATENTS FOR DIGESTIVES/PPIs
Table 4B5-5 SWITCH LIKELIHOOD OF DIGESTIVES/PPIs IN GERMANY

OVERVIEW [US$ 400]

AGOPTON [US$ 400]

Table 4B5-6 MANUFACTURER’S SALES OF AGOPTON IN GERMANY, 2001 TO 2003
Table 4B5-7 PRICES PAID BY THE GOVERNMENT FOR DIGESTIVES/PPIs IN GERMANY

ANTRA MUPS [US$ 400]

Table 4B5-8 MANUFACTURER’S SALES OF ANTRA MUPS IN GERMANY, 2001 TO 2003
Table 4B5-9 PRICES PAID BY THE GOVERNMENT FOR DIGESTIVES/PPIs IN GERMANY

NEXIUM [US$ 400]

Table 4B5-10 MANUFACTURER’S SALES OF NEXIUM IN GERMANY, 2001 TO 2003
Table 4B5-11 PRICES PAID BY THE GOVERNMENT FOR DIGESTIVES/PPIs IN GERMANY

PANTAZOL [US$ 400]

Table 4B5-12 MANUFACTURER’S SALES OF PANTAZOL IN GERMANY, 2001 TO 2003
Table 4B5-13 PRICES PAID BY THE GOVERNMENT FOR DIGESTIVES/PPIs IN GERMANY

PARIET [US$ 400]

Table 4B5-14 MANUFACTURER’S SALES OF PARIET IN GERMANY, 2001 TO 2003
Table 4B5-15 PRICES PAID BY THE GOVERNMENT FOR DIGESTIVES/PPIs IN GERMANY

HYPERTENTION MEDICATIONS [US$ 2 800]

OVERVIEW [US$ 400]

Table 4B6-1 HISTORICAL SALES OF PRESCRIPTION HYPERTENSION MEDICATIONS IN GERMANY, 2001 TO 2003
Table 4B6-2 SALES OF HYPERTENSION MEDICATIONS IN GERMANY, 2003
Table 4B6-3 PRICES PAID BY THE GOVERNMENT FOR HYPERTENSION MEDICATIONS IN GERMANY
Figure 4B6-1 EXPIRATIONS OF GERMAN PATENTS FOR HYPERTENSION MEDICATIONS
Table 4B6-4 SWITCH LIKELIHOOD OF HYPERTENSION MEDICATIONS IN GERMANY

DELIX [US$ 400]

Table 4B6-5 MANUFACTURER’S SALES OF DELIX IN GERMANY, 2001 TO 2003

DIVOAN [US$ 400]

Table 4B6-7 MANUFACTURER’S SALES OF DIOVAN IN GERMANY, 2001 TO 2003
Table 4B6-8 PRICED PAID BY THE GOVERNMENT FOR HYPERTENSION MEDICATIONS IN GERMANY

LORZAAR [US$ 400]

Table 4B6-9 MANUFACTURER’S SALES OF LORZAAR IN GERMANY, 2001 TO 2003
Table 4B6-10 PRICES PAID BY THE GOVERNMENT FOR HYPERTENSION MEDICATIONS IN GERMANY

MICARDIS [US$ 400]

Table 4B6-11 MANUFACTURER’S SALES OF MICARDIS/MICARDIS PLUS IN GERMANY, 2001 TO 2003

NORVASC [US$ 400]

Table 4B6-13 MANUFACTURER’S SALES OF NORVASC IN GERMANY, 2001 TO 2003

ZESTRIL [US$ 400]

Table 4B6-1 MANUFACTURER’S SALES OF ZESTRIL IN GERMANY, 2001 TO 2003

INCONTINENCE MEDICATIONS [US$ 1 200]

OVERVIEW [US$ 400]

Figure 4B7-1 EXPIRATIONS OF GERMAN PATENTS FOR INCONTINENCE MEDICATIONS
Table 4B7-1 HISTORICAL SALES OF PRESCRIPTION INCONTINENECE MEDICATIONS IN GERMANY, 2001 TO 2003
Table 4B7-2 MANUFACTURERS’ SALES OF PRESCRIPTION INCONTINENCE MEDICATIONS IN GERMANY, 2003
Table 4B7-3 PRICES PAID BY THE GOVERNMENT FOR INCONTINENCE MEDICATIONS IN GERMANY
Table 4B7-4 SWITCH LIKELIHOOD OF INCONTINENCE MEDICATIONS IN GERMANY

DETRUSITOL [US$ 400]

Table 4B7-5 MANUFACTURER’S SALES OF DETRUSITOL IN GERMANY, 2001 TO 2003
Table 4B7-6 PRICES PAID BY THE GOVERNMENT FOR INCONTINENCE MEDICATIONS IN GERMANY

DRIDASE [US$ 400]

Table 4B7-7 MANUFACTURER’S SALES OF DRIDASE IN GERMANY, 2001 TO 2003
Table 4B7-8 PRICES PAID BY THE GOVERNMENT FOR INCONTINENCE MEDICATIONS IN GERMANY

ANTI-OBESITY DRUGS[US$ 1 200]

OVERVIEW [US$ 400]

Table 4B8-1 HISTORICAL SALES OF PRESCRIPTION ANTI-OBESITY DRUGS IN GERMANY, 2001 TO 2003
Table 4B8-2 MANUFACTURERS SALES OF ANTI-OBESITY DRUGS IN GERMANY, 2003
Figure 4B8-1 EXPIRATIONS OF GERMAN PATENTS FOR ANTI-OBESITY DRUGS
Table 4B8-3 PRICES PAID BY THE GOVERNMENT FOR ANTI-OBESITY DRUGS IN GERMANY
Table 4B8-4 SWITCH LIKELIHOOD OF ANTI-OBESITY DRUGS IN GERMANY

REDUCTIL [US$ 400]

Table 4B8-5 MANUFACTURER’S SALES OF REDUCTIL IN GERMANY, 2001 TO 2003
Table 4B8-6 PRICES PAID BY THE GOVERNMENT FOR ANTI-OBESITY DRUGS IN GERMANY

XENICAL [US$ 400]

Table 4B8-7 MANUFACTURER’S SALES OF XENICAL IN GERMANY, 2001 TO 2003
Table 4B8-8 PRICES PAID BY THE GOVERNMENT FOR ANTI-OBESITY DRUGS IN GERMANY

ITALY [US$ 5 000]

OVERVIEW [US$ 3 000]

Table 4C 1 SELECTED CHARACTERISTICS OF ITALY
Figure 4C-1 HEALTH CARE EXPENDITURES OF SELECT COUNTRIES BY PERCENTAGE OF GDP, 2001
Table 4C 2 HEALTH CARE PROFILE OF ITALY
Figure 4C-2 PATIENT SATISFACTION WITH MEDICAL CARE IN ITALY, 2001
Table 4C-4 HISTORICAL SALES OF THE PHARMACEUTICAL MARKET IN ITALY, 2000 TO 2004
Table 4C-5 HISTORICAL SALES OF NONPRESCRIPTION DRUGS IN ITALY, 2001 TO 2004
Figure 4C-3 PHARMACEUTICAL SALES IN ITALY BY THERAPEUTIC CLASS, 2003
Figure 4C-4 PER-CAPITA PHARMACEUTICAL EXPENDITURES BY COUNTRY, 2004
Figure 4C-5 PHARMACEUTICAL EXPENDITURES AS A PERCENTAGE OF HEALTH CARE BY COUNTRY, 2001
Table 4C-6 TOP-SELLING PRESCRIPTION MEDICATIONS IN ITALY BY RANK, 2004
Table 4C-7 LIST OF RECENT RX-TO-OTC SWITCHES IN ITALY
Table 4C-8 LIST OF RECENT RX-TO-OTC SWITCHES THAT ARE ALLOWED TO ADVERTISE
Table 4C-9 SALES OF THE PHARMACEUTICAL MARKET IN ITALY BY SEGMENT, 2003
Figure 4C-6 GROWTH OF THE NONPRESCRIPTION MARKET IN ITALY, 2001 TO 2003
Figure 4C-7 MARKET SHARES OF THE NONPRESCRIPTION DRUG MARKET IN ITALY BY CLASS, 2003
Figure 4C-8 PER-CAPITA SPENDING OF OTC DRUGS BY COUNTRY, 2002
Table 4C-10 SPENDING ON ADVERTISING AS A PERCENTAGE OF SALES OF SELF-MEDICATION DRUGS IN ITALY
Table 4C-11 WHAT PREVENTS OTC SWITCHES AND GROWTH OF THE OTC MARKET IN ITALY
Table 4C-12 ACTIONS NEEDED TO FAVOR OTC SWITCHES AND GROWTH OF THE OTC MARKET IN ITALY
Table 4C-13 RX-TO-OTC SWITCH LIKELIHOOD OF PROFILED PRODUCTS IN ITALY

ANALGESICS AND ANTIRHEUMATICS [US$ 800]

OVERVIEW [US$ 400]

Table 4C1-1 SALES OF LEADING PRESCRIPTION ANALGESICS AND ANTIRHEUMATIC DRUGS IN ITALY, 2003
Figure 4C1-1 MARKET SHARES OF LEADING PRESCRIPTION ANALGESICS AND ANTIRHEUMATIC DRUGS IN ITALY, 2003
Table 4C1-2 MANUFACTURERS’ SALES OF OTC ANALGESICS AND ANTIRHEUMATICS IN ITALY, 2000 TO 2003
Table 4C1-3 RECENT RX-TO-OTC SWITCHES OF ANALGESICS AND ANTIRHEUMATICS IN ITALY
Table 4C1-4 SWITCH LIKELIHOOD OF ANALGESICS IN ITALY

CELEBREX [US$ 400]

Table 4C1-5 PRICES PAID BY THE PUBLIC FOR ANALGESICS IN ITALY

CHOLESTEROL REDUCERS [US$ 1 600]

OVERVIEW [US$ 400]

Figure 4C2-1 CARDIOVASCULAR DEATHS IN SELECTED COUNTRIES
Table 4C2-1 HISTORICAL MANUFACTURERS’ SALES OF PRESCRIPTION CHOLESTEROL REDUCERS IN ITALY, 2001 TO 2004
Table 4C2-2 MANUFACTURERS’ SALES OF PRESCRIPTION CHOLESTEROL REDUCERS IN ITALY BY ACTIVE INGREDIENT, 2001 TO 2004
Figure 4C2-2 MARKET SHARES OF PRESCRIPTION CHOLESTEROL REDUCERS IN ITALY BY ACTIVE INGREDIENT, 2004
Table 4C2-3 MANUFACTURERS’ SALES OF LEADING CHOLESTEROL REDUCERS IN ITALY BY BRAND, 2003
Figure 4C2-3 MARKET SHARES OF LEADING CHOLESTEROL REDUCERS IN ITALY BY BRAND, 2003
Table 4C2-4 PRICES PAID BY THE PUBLIC FOR CHOLESTEROL REDUCERS IN ITALY
Figure 4C2-4 EXPIRATIONS OF ITALIAN PATENTS FOR CHOLESTEROL REDUCERS
Table 4C2-5 SWITCH LIKELIHOOD OF CHOLESTEROL REDUCERS IN ITALY

ATORVASTATIN [US$ 400]

Table 4C2-6 MANUFACTURERS’ SALES OF TORVAST AND TOTALIP BRANDS OF ATORVASTATIN IN ITALY, 2003
Table 4C2-7 PRICES PAID BY THE PUBLIC FOR CHOLESTEROL REDUCERS IN ITALY

PRAVASTATIN [US$ 400]

Table 4C2-8 PRICES PAID BY THE PUBLIC FOR CHOLESTEROL REDUCERS IN ITALY

SIMVASTATIN [US$ 400]

Table 4C2-9 PRICES PAID BY THE PUBLIC FOR CHOLESTEROL REDUCERS IN ITALY

DIABETES MEDICATIONS [US$ 400]

Table 4C3-1 SELECT ORAL ANTIDIABETES DRUGS BY GUIDOTTI IN ITALY
Figure 4C3-1 GLOBAL NUMBERS OF PEOPLE AFFLICTED WITH DIABETES, 2000
Table 4C3-2 RETAIL SALES OF DIABETES MEDICATIONS IN ITALY, 2003
Table 4C3-3 RETAIL SALES OF LEADING DIABETES DRUGS IN ITALY, 2003
Figure 4C3-2 MARKET SHARE OF LEADING DIABETES DRUG MANUFACTURERS IN ITALY, 2003
Table 4C3-4 PRICES PAID BY THE PUBLIC FOR DIABETES MEDICATIONS IN ITALY

DIGESTIVES/PROTON PUMP INHIBITORS [US$ 1 600]

OVERVIEW [US$ 400]

Table 4C4-1 MANUFACTURERS’ SALES OF PRESCRIPTION PPIs IN ITALY, 2002 TO 2004
Figure 4C4-1 MARKET SHARES OF PRESCRIPTION PPIs IN ITALY, 2004
Table 4C4-2 MANUFACTURERS’ SALES OF NONPRESCRIPTION DIGESTIVES IN ITALY, 2000 TO 2003

LANSOPRAZOLE [US$ 400]

Table 4C4-4 MANUFACTURERS’ SALES OF LANSOPRAZOLE IN ITALY, 2002 TO 2004
Table 4C4-5 PRICES PAID BY THE PUBLIC FOR DIGESTIVES/PPIs IN ITALY

OMEPRAZOLE/ESOMEORAZOLE [US$ 400]

Table 4C4-6 MANUFACTURERS’ SALES OF OMEPRAZOLE AND ESOMEPRAZOLE IN ITALY, 2002 TO 2004
Table 4C4-7 PRICES PAID BY THE PUBLIC FOR DIGESTIVES/ PPIs IN ITALY

PANTOPRAZOLE [US$ 400]

Table 4C4-8 MANUFACTURERS’ SALES OF PANTOPRAZOLE IN ITALY, 2002 TO 2004
Table 4C4-9 PRICES PAID BY THE PUBLIC FOR DIGESTIVES/ PPIs IN ITALY

HYPERTENTION MEDICATIONS [US$ 800]

OVERVIEW [US$ 400]

Figure 4C5-1 GLOBAL PREVALENCE OF HYPERTENSION
Figure 4C5-2 PERCENTAGE OF PATIENTS WITH HYPERTENSION WHO ARE RECEIVING TREATMENT BY COUNTRY
Figure 4C5-3 CARDIOVASCULAR DEATHS BY COUNTRY
Figure 4C5-4 GLOBAL STROKE DEATHS BY COUNTRY
Table 4C5-1 HISTORICAL MANUFACTURERS’ SALES OF PRESCRIPTION HYPERTENSION MEDICATIONS IN ITALY, 2001 TO 2004
Table 4C5-2 MANUFACTURERS’ SALES OF LEADING PRESCRIPTION HYPERTENSION MEDICATIONS IN ITALY BY TYPE, 2001 TO 2004
Table 4C5-3 MANUFACTURERS’ SALES OF PRESCRIPTION HYPERTENSION MEDICATIONS IN ITALY BY BRAND, 2003
Figure 4C5-5 MARKET SHARES OF PRESCRIPTION HY-PERTENSION MEDICATIONS IN ITALY, 2003
Table 4C5-4 SWITCH LIKELIHOOD OF HYPERTENSION MEDICATIONS IN ITALY

NORVASC [US$ 400]

Table 4C5-5 PRICES PAID BY THE PUBLIC FOR HYPERTENSION MEDICATIONS IN ITALY

UNITED KINGDOM [US$ 8 000]

OVERVIEW [US$ 3 000]

Table 4D-1 SELECTED CHARACTERISTICS OF THE UNITED KINGDOM
Table 4D-2 MANUFACTURERS’ SALES OF THE TOP TEN PHARMACEUTICAL COMPANIES IN THE UNITED KINGDOM, 2003
Table 4D-3 MANUFACTURERS’ SALES OF THE TOP TEN PRESCRIPTION DRUGS IN THE UNITED KINGDOM, 2003
Table 4D-4 TOP FIVE REGISTERED RETAIL PHARMACIES IN THE UNITED KINGDOM BY NUMBER OF OUTLETS
Table 4D-5 OTC MARKET BREAKDOWN IN THE UNITED KINGDOM BY THERAPEUTIC CLASS, 2003
Table 4D-6 TOP TEN IMPORTED PRODUCTS BY PARALLEL TRADE IN THE UNITED KINGDOM BY MARKET SHARE, 2003
Table 4D-7 LIST OF RECENT Rx-To-OTC SWITCHES IN THE UNITED KINGDOM
Table 4D-8 Rx-TO-OTC SWITCH LIKELIHOOD OF PROFILED PRODUCTS IN THE UNITED KINGDOM

ANALGESICS [US$ 2 400]

Table 4D1-1 KEY PLAYERS IN THE U.K. OTC ANALGESICS MARKET, 2003
Table 4D1-2 HISTORICAL SALES OF PRESCRIPTION ANALGESICS IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D1-3 MANUFACTURERS’ U.K. SALES OF SELECTED PRESCRIPTION ANALGESICS, 2003
Table 4D1-4 MANUFACTURERS’ SALES OF SELECTED OTC INTERNAL ANALGESICS IN THE UNITED KINGDOM, 2003
Table 4D1-5 MANUFACTURERS’ SALES OF PRESCRIPTION ANTIMIGRAINE DRUGS IN THE UNITED KINGDOM, 2003
Table 4D1-6 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR ANALGESICS
Figure 4D1-1 EXPIRATIONS OF U.K. PATENTS FOR ANALGESICS
Table 4D1-7 SWITCH LIKELIHOOD OF ANALGESICS IN THE UNITED KINGDOM

OVERVIEW [US$ 400]

ARCOXIA [US$ 400]

Table 4D1-8 MANUFACTURER’S SALES OF ARCOXIA IN THE UNITED KINGDOM, 2002 AND 2003
Table 4D1-9 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR ANALGESICS

BEXTRA [US$ 400]

Table 4D1-10 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR ANALGESICS

CELEBREX [US$ 400]

Table 4D1-11 MANUFACTURER’S SALES OF CELEBREX IN THE UNITED KINGDOM, 2002 AND 2003
Table 4D1-12 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR ANALGESICS

IMIGRAN [US$ 400]

Table 4D1-13 MANUFACTURER’S SALES OF IMIGRAN IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D1-14 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR ANALGESICS

VIOXX [US$ 400]

CHOLESTEROL REDUCERS [US$ 2 400]

OVERVIEW [US$ 400]

Table 4D2-1 HISTORICAL SALES OF PRESCRIPTION CHOLESTEROL REDUCERS IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D2-2 MANUFACTURERS’ SALES OF CHOLESTEROL-LOWERING MEDICATIONS IN THE UNITED KINGDOM, 2003
Figure 4D2-1 MARKET SHARE OF KEY STATIN PRODUCTS IN THE UNITED KINGDOM, 2003
Table 4D2-3 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR CHOLESTEROL REDUCERS
Figure 4D2-2 EXPIRATIONS OF U.K. PATENTS FOR CHOLESTEROL REDUCERS
Table 4D2-4 SWITCH LIKELIHOOD OF CHOLESTEROL REDUCERS IN THE UNITED KINGDOM

CRESTOR [US$ 400]

Table 4D2-5 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR CHOLESTEROL REDUCERS

LESCOL [US$ 400]

Table 4D2-6 MANUFACTURER’S SALES OF LESCOL IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D2-7 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR CHOLESTEROL REDUCERS

LIPITOR [US$ 400]

Table 4D2-8 MANUFACTURER’S SALES OF LIPITOR IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D2-9 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR CHOLESTEROL REDUCERS

LIPOSTAT [US$ 400]

Table 4D2-10 MANUFACTURER’S SALES OF LIPOSTAT IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D2-11 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR CHOLESTEROL REDUCERS

ZOCOR [US$ 400]

Table 4D2-12 MANUFACTURER’S SALES OF ZOCOR IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D2-13 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR CHOLESTEROL REDUCERS

DIABETES MEDICATIONS [US$ 400]

Table 4D3-1 HISTORICAL SALES OF PRESCRIPTION DIABETES MEDICATIONS IN THE UNITED KINGDOM, 2001 TO 2003
Figure 4D3-1 EXPIRATIONS OF U.K. PATENTS FOR DIABETES MEDICATIONS
Table 4D3-3 PRICES PAID BY NHS FOR ORAL ANTI-DIABETES MEDICATIONS IN THE UNITED KINGDOM
Table 4D3-4 SWITCH LIKELIHOOD OF DIABETES MEDICATIONS IN THE UNITED KINGDOM

DIGESTIVES/PROTON PUMP INHIBITORS [US$ 2 400]

OVERVIEW [US$ 400]

Table 4D4-1 HISTORICAL SALES OF PRESCRIPTION PPIs IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D4-2 SALES OF PRESCRIPTION PPIs IN THE UNITED KINGDOM, 2003
Table 4D4-3 SALES OF THE LEADING OTC DIGESTIVES IN THE UNITED KINGDOM, 2002
Table 4D4-4 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR DIGESTIVES/PPIs
Table 4D4-5 SWITCH LIKELIHOOD OF DIGESTIVE/PPI PRODUCTS IN THE UNITED KINGDOM

LOSEC [US$ 400]

Table 4D4-6 MANUFACTURER’S SALES OF LOSEC IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D4-7 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR DIGESTIVES/PPIs

NEXIUM [US$ 400]

Table 4D4-8 MANUFACTURER’S SALES OF NEXIUM IN THE UNITED KINGDOM, 2002 AND 2003
Table 4D4-9 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR DIGESTIVES/PPIs

PARIET [US$ 400]

Table 4D4-10 MANUFACTURER’S SALES OF PARIET IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D4-11 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR DIGESTIVES/PPIs

PROTIUM [US$ 400]

Table 4D4-12 MANUFACTURER’S SALES OF PROTIUM IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D4-13 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR DIGESTIVES/PPIs

ZOTON [US$ 400]

Table 4D4-14 MANUFACTURER’S SALES OF ZOTON IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D4-15 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR DIGESTIVES/PPIs

HYPERTENSION MEDICATIONS [US$ 2 400]

OVERVIEW [US$ 400]

Table 4D5-1 HISTORICAL SALES OF PRESCRIPTION HYPERTENSION MEDICATIONS IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D5-2 MANUFACTURERS’ SALES OF HYPERTENSION MEDICATIONS IN THE UNITED KINGDOM, 2003
Table 4D5-3 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR HYPERTENSION MEDICATIONS
Figure 4D5-1 EXPIRATIONS OF U.K. PATENTS FOR HYPERTENSION MEDICATIONS
Table 4D5-4 SWITCH LIKELIHOOD OF HYPERTENSION MEDICATIONS IN THE UNITED KINGDOM

COZAAR [US$ 400]

Table 4D5-5 MANUFACTURER’S SALES OF COZAAR IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D5-6 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR HYPERTENSION MEDICATIONS

DIOVAN [US$ 400]

Table 4D5-7 MANUFACTURER’S SALES OF DIOVAN IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D5-8 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR HYPERTENSION MEDICATIONS

ISTIN [US$ 400]

Table 4D5-9 MANUFACTURER’S SALES OF ISTIN IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D5-10 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR HYPERTENSION MEDICATIONS

TRITACE [US$ 400]

Table 4D5-11 MANUFACTURER’S SALES OF TRITACE IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D5-12 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR HYPERTENSION MEDICATIONS

ZESTRIL [US$ 400]

Table 4D5-13 MANUFACTURER’S SALES OF ZESTRIL IN THE UNITED KINGDOM, 2001 TO 2003
Table 4D5-14 PRICES PAID BY NHS IN THE UNITED KINGDOM FOR HYPERTENSION MEDICATIONS

NORTH AMERICA

CANADA [US$ 6 500]

OVERVIEW [US$ 4 000]

Table 5A 1 SELECTED CHARACTERISTICS OF CANADA
Table 5A 2 MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS IN CANADA BY VALUE, 2002 AND 2003
Table 5A 3 SALES OF SWITCH CANDIDATES IN CANADA AT THE MANUFACTURER’S LEVEL, 2003
Table 5A 4 PRIVATE-LABEL SALES OF OTC PRODUCTS IN CANADA AT THE MANUFACTURER’S LEVEL, 2003
Table 5A 5 HARMONIZATION STATUS OF NATIONAL DRUG SCHEDULES IN CANADA BY PROVINCE
Table 5A 6 RX-TO-OTC SWITCHES IN CANADA, 1986 TO 2004
Table 5A 7 RX-TO-OTC SWITCH LIKELIHOOD OF PROFILED PRODUCTS IN CANADA

ANALGESICS [US$ 1 200]

OVERVIEW [US$ 400]

Table 5A1 1 MANUFACTURERS’ SALES OF NONPRESCRIPTION NSAIDs IN CANADA, 2003
Table 5A1 2 MANUFACTURERS’ SALES OF PRESCRIPTION ARTHRITIS PAIN RELIEVERS IN CANADA, 2003
Table 5A1 3 MANUFACTURERS’ SALES OF NONPRESCRIPTION GENERAL PAIN RELIEVERS IN CANADA, 2003
Table 5A1 4 MANUFACTURERS’ SALES OF PRESCRIPTION MIGRAINE TREATMENTS DRUGS IN CANADA, 2003
Figure 5A1 1 EXPIRATIONS OF CANADIAN PATENTS FOR ANALGESICS
Figure 5A1 2 EXPIRATIONS OF CANADIAN PATENTS FOR MIGRAINE DRUGS
Table 5A1 5 SWITCH LIKELIHOOD OF ANALGESICS IN CANADA

CELEBREX [US$ 400]

Table 5A1-6 MANUFACTURER’S SALES OF CELEBREX IN CANADA, 2001 TO 2003
Table 5A1-7 SALES AND MARKET SHARE OF PFIZER AND PHARMACIA’S RX-TO-OTC SWITCHES IN THE UNITED STATES, 2003
Table 5A1-8 SALES AND MARKET SHARE OF PFIZER AND PHARMACIA’S RX-TO-OTC SWITCHES IN CANADA, 2003
Table 5A1-9 RELATIVE CANADIAN PRICES OF COX 2 INHIBITORS

IMITREX [US$ 400]

Table 5A1 10 MANUFACTURER’S SALES OF IMITREX IN CANADA
Table 5A1 11 SALES AND MARKET SHARE OF GLAXOSMITHKLINE’S RX-TO-OTC SWITCHES IN THE UNITED STATES, 2003
Table 5A1 12 RELATIVE CANADIAN PRICES OF Rx TRIPTANS

CHOLESTEROL REDUCERS [US$ 2 400]

OVERVIEW [US$ 400]

Table 5A2 1 SALES OF PRESCRIPTION CHOLESTEROL REDUCERS AT THE MANUFACTURER’S LEVEL IN CANADA, 2003
Figure 5A2 1 EXPIRATIONS OF CANADIAN PATENTS FOR CHOLESTEROL REDUCERS
Table 5A2 2 SWITCH LIKELIHOOD OF CHOLESTEROL REDUCER PRODUCTS IN CANADA

LESCOL [US$ 400]

Table 5A2 3 MANUFACTURER’S SALES OF LESCOL IN CANADA, 2001 TO 2003
Table 5A2 4 NOVARTIS’ RX-TO-OTC SWITCHES IN THE UNITED STATES
Table 5A2 5 RELATIVE CANADIAN PRICES OF Rx CHOLESTEROL REDUCERS

LIPITOR [US$ 400]

Table 5A2 6 MANUFACTURER’S SALES OF LIPITOR IN CANADA, 2001 TO 2003
Table 5A2 7 SALES AND MARKET SHARE OF PFIZER AND PHARMACIA’S RX-TO-OTC SWITCHES IN THE UNITED STATES, 2003
Table 5A2 8 SALES AND MARKET SHARE OF PFIZER AND PHARMACIA’S RX-TO-OTC SWITCHES IN CANADA, 2003
Table 5A2 9 RELATIVE CANADIAN PRICES OF PRESCRIPTION CHOLESTEROL REDUCERS

MEVACOR [US$ 400]

Table 5A2 10 MANUFACTURER’S SALES OF MEVACOR IN CANADA, 2001 TO 2003
Table 5A2 11 RELATIVE CANADIAN PRICES OF Rx CHOLESTEROL REDUCERS

PRAVACHOL [US$ 400]

Table 5A2 12 MANUFACTURER’S SALES OF PRAVACHOL IN CANADA, 2001 TO 2003
Table 5A2 13 RELATIVE CANADIAN PRICES OF Rx CHOLESTEROL REDUCERS

ZOCOR [US$ 400]

Table 5A2 14 MANUFACTURER’S SALES OF ZOCOR IN CANADA, 2001 TO 2003
Table 5A2 15 RELATIVE CANADIAN PRICES OF Rx CHOLESTEROL REDUCERS

DIABETES MEDICATIONS [US$ 800]

OVERVIEW [US$ 400]

Table 5A3 1 SALES OF PRESCRIPTION DIABETES MEDICATIONS (Excluding Insulin), 2003
Figure 5A3 1 EXPIRATIONS OF CANADIAN PATENTS FOR DIABETES MEDICATIONS
Table 5A3 2 SWITCH LIKELIHOOD OF GLUCOPHAGE IN CANADA

GLUCOPHAGE [US$ 400]

Table 5A3 3 MANUFACTURER’S SALES OF GLUCOPHAGE IN CANADA, 2001 TO 2003
Table 5A3 4 RELATIVE CANADIAN PRICES OF Rx DIABETES MEDICATIONS

DIGESTIVES/PROTON PUMP INHIBITORS [US$ 1 600]

OVERVIEW [US$ 400]

Table 5A4 1 SALES OF NONPRESCRIPTION ANTACIDS IN CANADA, 2002 AND 2003
Table 5A4 2 SALES OF PRESCRIPTION PPIs IN CANADA, 2003
Table 5A4 3 SWITCH LIKELIHOOD OF DIGESTIVE/PPI PRODUCTS IN CANADA

LOSEC [US$ 400]

Table 5A4 4 MANUFACTURER’S SALES OF LOSEC IN CANADA, 2001 TO 2003
Table 5A4 5 SALES OF PROCTER & GAMBLE’S RX-TO-OTC SWITCHES IN THE UNITED STATES, 2003
Table 5A4 6 RELATIVE CANADIAN PRICES OF RX GASTRO-INTESTINAL DRUGS

PANTOLOC [US$ 400]

Table 5A4 7 MANUFACTURER’S SALES OF PANTOLOC IN CANADA, 2001 TO 2003
Table 5A4 8 MANUFACTURER’S SALES OF WYETH’S RX-TO-OTC SWITCHES IN THE UNITED STATES, 2003
Table 5A4 9 RELATIVE CANADIAN PRICES OF RX GASTRO-INTESTINAL DRUGS

PREVACID [US$ 400]

Table 5A4-10 MANUFACTURER’S SALES OF PREVACID IN CANADA, 2001 TO 2003
Table 5A4-11 RELATIVE CANADIAN PRICES OF PRESCRIPTION GASTRO-INTESTINAL DRUGS

OSTEOPOROSIS MEDICATIONS [US$ 1 500]

OVERVIEW [US$ 400]

Table 5A5 1 SALES OF PRESCRIPTION OSTEOPOROSIS MEDICATIONS IN CANADA, 2003
Table 5A5 2 SALES OF NONPRESCRIPTION CALCIUM SUPPLEMENTS IN CANADA, 2003
Figure 5A5 1 EXPIRATIONS OF CANADIAN PATIENTS FOR LEADING OSTEOPOROSIS DRUGS
Table 5A5 3 SWITCH LIKELIHOOD OF OSTEOPOROSIS MEDICATIONS IN CANADA

DIDROCAL [US$ 400]

Table 5A5 4 MANUFACTURER’S SALES OF DIDROCAL IN CANADA, 2001 TO 2003
Table 5A5 5 SALES OF PROCTER & GAMBLE’S RX-TO-OTC SWITCHES IN THE UNITED STATES, 2003
Table 5A5 6 RELATIVE CANADIAN PRICES OF OSTEOPOROSIS DRUGS

EVISTA [US$ 400]

Table 5A5 7 MANUFACTURER’S SALES OF EVISTA IN CANADA, 2001 TO 2003
Table 5A5 8 RELATIVE CANADIAN PRICES OF OSTEOPOROSIS DRUGS

FOSAMAX [US$ 400]

Table 5A5 9 MANUFACTURER’S SALES OF FOSAMAX IN CANADA, 2001 TO 2003
Table 5A5 10 RELATIVE CANADIAN PRICES OF OSTEOPOROSIS DRUGS

UNITED STATES OF AMERICA [US$ 8 000]

OVERVIEW [US$ 4 000]

Table 5B-1 SELECTED CHARACTERISTICS OF THE UNITED STATES OF AMERICA
Table 5B-2 U.S. SALES OF NONPRESCRIPTION DRUGS RANKED BY PERCENTAGE CHANGE, 2002 AND 2003
Figure 5B-1 CUSTOMER SEGMENTS OF THE U.S. PHARMACEUTICAL MARKET, 2002
Figure 5B-2 U.S. SALES OF NONPRESCRIPTION DRUGS BY RETAIL OUTLET, 2003
Figure 5B-3 STEPS TOWARD DRUG APPROVAL IN THE UNITED STATES
Figure 5B-4 OTC DRUG MONOGRAPH REVIEW PROCESS IN THE UNITED STATES
Figure 5B-5 RX-TO-OTC SWITCH PROCESS IN THE UNITED STATES
Figure 5B-6 HEALTH CARE FINANCING IN THE UNITED STATES, 2002
Table 5B-4 MANUFACTURERS’ SALES OF MAJOR RX-TO-OTC SWITCHES IN THE UNITED STATES, 2003
Table 5B-5 RX-TO-OTC SWITCH LIKELIHOOD OF PROFILED PRODUCTS IN THE UNITED STATES
Table 5B-6 AVERAGE PRESCRIPTION PRICES IN THE UNITED STATES, 2002 AND 2003

ALLERGY MEDICATIONS [US$ 2 000]

OVERVIEW [US$ 400]

Table 5B1-1 MANUFACTURERS’ SALES OF PRESCRIPTION ALLERGY MEDICATIONS IN THE UNITED STATES, 2003
Figure 5B1-1 MARKET SHARES OF PRESCRIPTION ALLERGY RELIEF MEDICATIONS IN THE UNITED STATES, 2004
Table 5B1-2 MANUFACTURERS’ SALES OF OTC ALLERGY MEDICATIONS IN THE UNITED STATES BY BRAND, 2002 AND 2003
Table 5B1-3 HISTORICAL SALES OF PRESCRIPTION ALLERGY MEDICATIONS IN THE UNITED STATES, 2001 TO 2003
Figure 5B1-2 EXPIRATIONS OF U.S. PATENTS FOR ALLERGY MEDICATIONS
Table 5B1-4 SWITCH LIKELIHOOD OF ALLERGY MEDICATIONS IN THE UNITED STATES

ALLEGRA [US$ 400]

Table 5B1-5 MANUFACTURER’S SALES OF ALLEGRA IN THE UNITED STATES, 2001 TO 2003
Table 5B1-6 TRACEABLE MEDIA EXPENDITURES FOR ALLEGRA IN THE UNITED STATES, 2003
Table 5B1-7 ESTIMATED PRICES PAID FOR ALLERGY MEDICATIONS IN THE UNITED STATES

CLARITIN [US$ 400]

Table 5B1-8 CHRONOLOGY OF EVENTS IN PETITION TO FORCE LORATADINE TO SWITCH TO OTC STATUS
Table 5B1-9 SALES OF CLARITIN PRE- AND POST-SWITCH, 2000 TO 2004
Table 5B1-10 SALES OF CLARINEX IN THE UNITED STATES, 2002 TO 2004
Table 5B1-11 SALES OF PRESCRIPTION ALLERGY MEDICATION IN THE UNITED STATES, 2001 TO 2003
Table 5B1-12 SALES OF NONPRESCRIPTION ALLERGY MEDICATIONS IN THE UNITED STATES, 2001 TO 2004
Table 5B1-13 MANUFACTURERS’ SALES OF OTC ALLERGY RELIEF PRODUCTS IN THE UNITED STATES, 2002 TO 2004
Table 5B1-14 TRACEABLE MEDIA EXPENDITURES FOR CLARITIN, 2003

FLONASE [US$ 400]

Table 5B1-15 MANUFACTURER’S SALES OF FLONASE IN THE UNITED STATES, 2001 TO 2003
TABLE 5B1-16 TRACEABLE MEDIA EXPENDITURES FOR FLONASE IN THE UNITED STATES, 2003
Table 5B1-17 ESTIMATED PRICES PAID FOR ALLERGY MEDICATIONS IN THE UNITED STATES

ZYRTEC [US$ 400]

Table 5B1-18 MANUFACTURER’S SALES OF ZYRTEC IN THE UNITED STATES, 2001 TO 2003
Table 5B1-19 TRACEABLE MEDIA EXPENDITURES FOR ZYRTEC, 2003
Table 5B1-20 ESTIMATED PRICES PAID FOR ALLERGY MEDICATIONS IN THE UNITED STATES

CHOLESTEROL REDUCERS [US$ 2 000]

OVERVIEW [US$ 400]

Table 5B2-1 CLASSES OF CHOLESTEROL REDUCER MEDICATIONS IN THE UNITED STATES AND THEIR EFFECTS ON HIGH BLOOD CHOLESTEROL
Table 5B2-2 NATIONAL HEART, LUNG, AND BLOOD INSTITUTE’S CHOLESTEROL LEVELS AND RATINGS
Table 5B2-3 MANUFACTURERS’ SALES OF PRESCRIPTION CHOLESTEROL REDUCERS IN THE UNITED STATES, 2003
Figure 5B2-1 MARKET SHARES OF PRESCRIPTION CHOLESTEROL REDUCERS IN THE UNITED STATES, 2003
Table 5B2-4 MANUFACTURERS’ SALES OF PRESCRIPTION REDUCERS IN THE UNITED STATES, 2001 TO 2003
Table 5B2-5 SALES OF SELECT OTC PRODUCTS FOR CHOLESTEROL MAINTENANCE IN THE UNITED STATES, 2003
Figure 5B2-2 EXPIRATIONS OF U.S. PATENTS FOR CHOLESTEROL REDUCERS
Table 5B2-6 SWITCH LIKELIHOOD OF CHOLESTEROL REDUCERS IN THE UNITED STATES

LIPITOR [US$ 400]

Table 5B2-7 MANUFACTURER’S SALES OF LIPITOR IN THE UNITED STATES, 2001 TO 2004
Table 5B2-8 TRACEABLE MEDIA EXPENDITURES FOR LIPITOR, 2003
Table 5B2-9 ESTIMATED PRICES PAID FOR CHOLESTEROL REDUCERS IN THE UNITED STATES

MEVACOR [US$ 400]

Table 5B2-10 MANUFACTURER’S SALES OF MEVACOR IN THE UNITED STATES, 2001 TO 2004
Table 5B2 11 JOHNSON & JOHNSON–MERCK’S SALES OF NONPRESCRIPTION DRUGS, 2002 AND 2003
Table 5B2-12 ESTIMATED PRICES PAID FOR CHOLESTEROL REDUCERS IN THE UNITED STATES

PRAVACHOL [US$ 400]

Table 5B2-13 MANUFACTURER’S SALES OF PRAVACHOL IN THE UNITED STATES, 2001 TO 2003
Table 5B2-14 TRACEABLE MEDIA EXPENDITURES FOR PRAVACHOL, 2003
Table 5B2-15 ESTIMATED PRICES PAID FOR CHOLESTEROL REDUCERS IN THE UNITED STATES

ZOCOR [US$ 400]

Table 5B2-16 MANUFACTURER’S SALES OF ZOCOR IN THE UNITED STATES, 2001 TO 2004
Table 5B2 17 JOHNSON & JOHNSON–MERCK’S SALES OF NONPRESCRIPTION DRUGS, 2002 AND 2003
Table 5B2-18 TRACEABLE MEDIA EXPENDITURES FOR ZOCOR, 2003
Table 5B2-19 ESTIMATED PRICES PAID FOR CHOLESTEROL REDUCERS IN THE UNITED STATES

DIGESTIVES/PPIS [US$ 1 600]

OVERVIEW [US$ 400]

Table 5B3-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION ANTACIDS AND ANTIGAS PRODUCTS, 2003
Table 5B3 2 MANUFACTURERS’ SALES OF PROTON PUMP INHIBITORS, 2001 TO 2004
Figure 5B3-1 EXPIRATIONS OF U.S. PATENTS FOR PROTON PUMP INHIBITORS
Table 5B3-3 SWITCH LIKELIHOOD OF PROTON PUMP INHIBITORS IN THE UNITED STATES

NEXIUM [US$ 400]

Table 5B3-4 MANUFACTURER’S SALES OF NEXIUM IN THE UNITED STATES, 2001 TO 2004
Table 5B3-5 TRACEABLE MEDIA EXPENDITURES FOR NEXIUM, 2003
Table 5B3-6 ESTIMATED PRICES PAID FOR PPIs IN THE UNITED STATES

PREVACID [US$ 400]

Table 5B3-7 MANUFACTURER’S SALES OF PREVACID IN THE UNITED STATES, 2001 TO 2004
Table 5B3-8 TRACEABLE MEDIA EXPENDITURES FOR PREVACID, 2003
Table 5B3-9 ESTIMATED PRICES PAID FOR PPIs IN THE UNITED STATES

PROTONIX [US$ 400]

Table 5B3-10 MANUFACTURER’S SALES OF PREVACID IN THE UNITED STATES, 2001 TO 2004
Table 5B3-11 ESTIMATED PRICES PAID FOR PPIs IN THE UNITED STATES

INCONTINENCE MEDICATIONS [US$ 1 200]

OVERVIEW [US$ 400]

Table 5B4-1 MANUFACTURERS’ SALES OF PRESCRIPTION INCONTINENCE MEDICATIONS IN THE UNITED STATES, 2001 TO 2004
Table 5B4-2 MANUFACTURERS’ SALES OF PRESCRIPTION INCONTINENCE MEDICATIONS IN THE UNITED STATES, 2004
Figure 5B4-1 MARKET SHARES OF PRESCRIPTION INCONTINENCE MEDICATIONS, 2004
Figure 5B4-2 EXPIRATIONS OF U.S. PATENTS FOR INCONTINENCE MEDICATIONS
Table 5B4-3 SWITCH LIKELIHOOD OF INCONTINENCE MEDICATIONS IN THE UNITED STATES

DETROL [US$ 400]

Table 5B4-4 MANUFACTURER’S SALES OF DETROL IN THE UNITED STATES, 2001 TO 2004
Table 5B4-5 TRACEABLE MEDIA EXPENDITURES FOR DETROL LA, 2003
Table 5B4-6 ESTIMATED PRICES PAID FOR INCONTINENCE MEDICATIONS IN THE UNITED STATES

DITROPAN [US$ 400]

Table 5B4-7 MANUFACTURER’S SALES OF DITROPAN IN THE UNITED STATES, 2001 TO 2004
Table 5B4-8 TRACEABLE MEDIA EXPENDITURES FOR DITROPAN, 2003
Table 5B4-9 ESTIMATED PRICES PAID FOR INCONTINENCE MEDICATIONS IN THE UNITED STATES

ANTI-OBESITY DRUGS [US$ 1 200]

OVERVIEW [US$ 400]

Table 5B5-1 MANUFACTURERS’ SALES OF PRESCRIPTION ANTI-OBESITY DRUGS IN THE UNITED STATES, 2001 TO 2004
Table 5B5-2 MANUFACTURERS’ SALES OF PRESCRIPTION ANTI-OBESITY DRUGS IN THE UNITED STATES, 2004
Figure 5B5-1 MARKET SHARES OF PRESCRIPTION ANTI-OBESITY DRUGS, 2004
Figure 5B5-2 EXPIRATIONS OF U.S. PATENTS FOR ANTI-OBESITY DRUGS
Table 5B5-3 SWITCH LIKELIHOOD OF ANTI-OBESITY DRUGS IN THE UNITED STATES

MERIDIA [US$ 400]

Table 5B5-4 MANUFACTURER’S SALES OF MERIDIA IN THE UNITED STATES, 2001 TO 2004
Table 5B5-5 ESTIMATED PRICES PAID FOR ANTI-OBESITY DRUGS IN THE UNITED STATES

XENICAL [US$ 400]

Table 5B5-6 MANUFACTURER’S SALES OF XENICAL IN THE UNITED STATES, 2001 TO 2004
Table 5B5-7 TRACEABLE MEDIA EXPENDITURES FOR XENICAL, 2003
Table 5B5-8 ESTIMATED PRICES PAID FOR ANTI-OBESITY DRUGS IN THE UNITED STATES

STEP 2 of 3

– Provide your contact information:

All fields in *BOLD are required.

*Name:
*Title:
*Company/Division:
*Address 1 :
Address 2 :
*City:
*State/Province:
*Zip/Postal code:
*Country:
*Phone:
Fax:
*Email:

STEP 3 of 3

– Review and accept our subscription terms and conditions by viewing and clicking below:

*Please view our terms and conditions, and check this box to indicate your acceptance of these terms and conditions.

Thank you for your interest in subscribing to our syndicated reports. To complete this process, please click on the button below and a member of our global sales team will contact you shortly to confirm the final price and complete the transaction. Upon acceptance of your order, we will deliver the files in PDF format via email.

Market Research: International Rx-to-OTC Switch Forecasts

International Rx-to-OTC Switch Forecasts

ORDER ONLINE

STEP 1 of 3

STEP 2 of 3

STEP 3 of 3

Questions?

Market Research: International Rx-to-OTC Switch
Forecasts